All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
On April 17, 2023, omidubicel-onlv, a substantially modified allogeneic cord blood-based cell therapy, which has been discussed previously on the AML Hub here, here and here, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult and pediatric patients aged ≥12 years with hematologic malignancies who are eligible for umbilical cord blood transplantation following myeloablative conditioning.1 Omidubicel-onlv contains stem cells derived from umbilical cord blood from an allogeneic pre-screened donor that are processed and cultured with nicotinamide before being administered as a single intravenous dose.1
This approval is based on results from a phase III randomized, multicenter study (NCT02730299) demonstrating efficacy and an acceptable safety profile of omidubicel-onlv compared with standard umbilical cord blood transplantation in 125 patients aged 12–65 years with acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndromes, or lymphoma.1 The trial notably included a high proportion of patients who were non-white (44%), a historically underrepresented population in registries of unrelated adult donors and umbilical cord blood.2
As with all umbilical cord products, omidubicel-onlv has a Boxed Warning for infusion reactions, graft-versus-host disease, engraftment syndrome, and graft failure.1
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox